- Home
- PSF vs NKTX Comparison
PSF vs NKTX Comparison
Compare PSF & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- NKTX
- Stock Information
- Founded
- PSF 2010
- NKTX 2015
- Country
- PSF United States
- NKTX United States
- Employees
- PSF N/A
- NKTX N/A
- Industry
- PSF Investment Managers
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- NKTX Health Care
- Exchange
- PSF Nasdaq
- NKTX Nasdaq
- Market Cap
- PSF 246.0M
- NKTX 225.1M
- IPO Year
- PSF N/A
- NKTX 2020
- Fundamental
- Price
- PSF $20.15
- NKTX $2.53
- Analyst Decision
- PSF
- NKTX Strong Buy
- Analyst Count
- PSF 0
- NKTX 5
- Target Price
- PSF N/A
- NKTX $17.00
- AVG Volume (30 Days)
- PSF 25.0K
- NKTX 1.0M
- Earning Date
- PSF 01-01-0001
- NKTX 11-07-2024
- Dividend Yield
- PSF 7.69%
- NKTX N/A
- EPS Growth
- PSF N/A
- NKTX N/A
- EPS
- PSF N/A
- NKTX N/A
- Revenue
- PSF N/A
- NKTX N/A
- Revenue This Year
- PSF N/A
- NKTX N/A
- Revenue Next Year
- PSF N/A
- NKTX N/A
- P/E Ratio
- PSF N/A
- NKTX N/A
- Revenue Growth
- PSF N/A
- NKTX N/A
- 52 Week Low
- PSF $16.00
- NKTX $2.36
- 52 Week High
- PSF $20.19
- NKTX $16.24
- Technical
- Relative Strength Index (RSI)
- PSF 34.31
- NKTX 27.13
- Support Level
- PSF $20.40
- NKTX $2.92
- Resistance Level
- PSF $21.10
- NKTX $3.81
- Average True Range (ATR)
- PSF 0.20
- NKTX 0.30
- MACD
- PSF -0.04
- NKTX -0.03
- Stochastic Oscillator
- PSF 10.75
- NKTX 3.76
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.